CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed Inc. announced that its oral drug candidate, neflamapimod, has been granted an Innovation Passport designation under the UK Innovative Licensing and Access Pathway (ILAP) to support accelerated regulatory review and patient access for the treatment of Dementia with Lewy Bodies (DLB). This designation recognizes neflamapimod's potential as …